
|Articles|January 18, 2002
Voluntary Recall of Antihemophilic Factor (Recombinant), Helixate FS / Kogenate FS
Author(s)BioPharm International Editors
Potency testing following nine weeks storage at room temperature found that the lots fell below the minimum potency specification.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Top 10 BioPharm International Articles of 2025
3
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
4
Abzena Discusses Novel Approaches to Bioconjugation: Part One of Three
5




